People

• Mass spectrometry imaging (MSI) of tissues and other sample surfaces for targeted and untargeted analysis
• MSI and LCMS based metabolomics and lipidomics for biomarkers discovery
• Understand the role of metabolites & lipids in signaling pathway in disease models using MSI and LCMS/MS

Cancer research and development, drug discovery of antitumoral agents, targeted therapies, molecular imaging as innovative tool of diagnosis and treatment of brain tumours, medicinal chemistry of PARP inhibitors, radiochemistry, pre-clinical studies.

Dr Pimlott is the principal radiochemist in the research and development radiopharmaceutical group, based at the Radionuclide Dispensary, Western Infirmary, Glasgow. Her research is focused on the development of novel molecular imaging agents. This includes:-

• the development of novel radiolabelling methodologies
• the synthesis and evaluation of novel tracer candidates using both in vitro and in vivo imaging techniques
• the development of novel in vitro methodologies for the prediction of radiotracer in vivo characteristics.

Dr Pimlott is also experienced in the provision of radiopharmaceuticals for clinical research studies in compliance with Good Manufacturing Practice standards. Research is funded by the SINAPSE, Wellbeing of Women, Translational Medicine Research Collaboration (TMRC), Neurosciences Foundation, Chief Scientist Office (Scottish Executive), Medical Research Scotland and GE Healthcare.